Providing high quality reagents for 3D printing human tissue models
OUR BIOINK TECHNOLOGY
Compatible with multiple bioprinters
High cell viability post printing
Beta tested by industry leaders
Xeno-free
Reduces time and labor costs
Designed for use with fragile cells
AWARDS & RECOGNITION
MEET THE TEAM
Dr. Stephanie Willerth
~
CEO
Dr. Willerth is a full professor of Biomedical Engineering who runs an active research group that investigates how to engineer neural tissue from pluripotent stem cells. Her research group has developed many types of biomaterial scaffolds for promoting the differentiation of induced pluripotent
stem cells (iPSCs) into neural phenotypes for tissue engineering applications, such as screening the toxicity of drugs, learning about how tissues form during development and replacing dysfunctional tissues. She founded Axolotl Biosciences with the goal of bioprinting neural tissues easily accessible to scientists and engineering from a range of backgrounds.
Dr. Laura De La Vega
~
Co-Founder
Dr. Laura De La Vega is a scientist and bioengineer who's passionate about basic, translational science and innovative technologies. She holds expertise in the fields of stem cells, biomaterials, and biotechnology involving the development of technological applications using biological systems. She completed her PhD at the University of Victoria where she developed novel techniques for engineering neural tissue under the direction of Dr. Willerth. Her goal in co-founding Axolotl Biosciences is to optimize bioinks for multiple bioprinting platforms and address customer needs within the 3D bioprinting industry.
Laila Abelseth
~
Co-Founder
Laila completed an Undergraduate Degree in Biomedical Engineering at the University of Victoria. During the final year of her degree she focused on cell culture and tissue engineering by completing two work terms in Dr.Willerth's lab and incorporating
tissue engineering into her honours and final capstone projects. Through her work with Axolotl Biosciences, she wants to contribute to advancements in tissue engineering and biological research which will hopefully lead to improved healthcare.
SUPPORTED BY:
PUBLICATIONS
3D printing of neural tissues derived from human induced pluripotent stem cells using a fibrin-based bioink
ACS Biomaterials Science and Engineering. 2018;5(1):234-43
E. Abelseth, L. Abelseth, L. De la Vega, S.T. Beyer, S.J.Wadsworth, S.M. Willerth
Bioprinting a novel glioblastoma tumor model using a fibrin based bioink for drug screening
Materials Today Chemistry. 2019, (12). 78-84
C. Lee, E. Abelseth, L. de la Vega, S.M. Willerth
3D bioprinting human induced pluripotent stem cell-derived neural tissues using a novel lab-on-a-printer technology
Applied Science. 2018. 2018, 8(2414). 1-13
L. De la Vega, D.A. Rosas Gómez, E. Abelseth, L. Abelseth, V.A. da Silva, S.M. Willerth
3D bioprinting pluripotent stem cell derived neural tissues using a novel fibrin bioink containing drug releasing microspheres
Frontiers in Bioengineering and Biotechnology. 2020, 8(57)
R. Sharma, I.P.M. Smits, L. De la Vega, C. Lee, S.M. Willerth
Novel N-cadherin antagonist causes glioblastoma cell death in a 3D bioprinted co-culture model
Biochemical and Biophysical Research Communications. 2020. 2020, 527(2),162-168
I.P.M. Smits, O.W. Blaschuk, S.M. Willerth
3D bioprinting human pluripotent stem cells and drug releasing microspheres to produce responsive neural tissue
Advanced NanoBioMed Research. 2000077. 1-16.
L. De la Vega, L. Abelseth, R. Sharma, J. Triviño-Paredes, M. Restan, S.M. Willerth
